Cabel ... yes! That would have been a good question. I'm not knowledgable about the regulatory bodies, nor ins & outs of utlizing things in other parts of the world while pursuing FDA approvals? But same old story ... 1) data data data (efficacy), 2) safety profile, 3) healthcare costs savings impact

And yeah it would be quite interesting if other parts of the world were less hung up on a small statistical miss over the perceived benefits. I mean, even if it were only 90% confidence, rather than 95% ..... um, that's still a lot of people and a very high % of benefit, per the data data data ... maybe?

On a side note, if I am final stages with cardio or renal issues, or even advanced cognitive issues, and maxed out on available therapies? ... and apabetalone is only 25% confidence index (haha), with the known safety profile I want to try it.